Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Iemand een idee waarom het aandeel vandaag ineens wel sterk kan stijgen, meer dan 5%. Op de site zie ik geen aanleiding.
Terra2000 schreef op 2 november 2016 13:03 :
Iemand een idee waarom het aandeel vandaag ineens wel sterk kan stijgen, meer dan 5%. Op de site zie ik geen aanleiding.
Zo mag het van mij nog wel een paar weken verder gaan.
Op het forum van Genfit staat dat dit bedrijf na het succes van de recente kapitaalsverhoging extra middelen heeft om zijn strategie te financieren. Met name de verdere ontwikkeling van het klinische fase III programma van Elafibraor, het vlaggenschip in NASH. De resultaten van dit onderzoek worden verwacht eind 2018. Als ze positief zijn kan Genfit een voorwaardelijke vergunning krijgen eind 2019 of begin 2020. CM-CIC analisten zien een zeer belangrijke marktkans als het bedrijf de verschillende fasen met succes passeert. Aangenomen wordt dat het Elafibranor proces een 100% kans op succes wordt en dat het in 2020 op € 207,00 zal staan, een vertienvoudiging. Do not shoot the pianist....
If successful, CM - CIC Securities see #Genfit €207 by 2020. Over rendement gesproken :)
Genfit FDA cleared IND to proceed with Phase II trial and evaluate elafibranor in PBC Goed nieuws!
Intercept (ICPT) Moeilijkheidsgraad: GENFIT om ervan te genieten? Geplaatst op 4 november 2016 door Schrijven BiotechBourse © in Nieuws , Producten De belangrijkste concurrent van GENFIT, dat is de meest geavanceerde in de race voor de behandeling van NASH, werd onlangs zwaar gestraft: zijn cursus is meer dan 40% verloren in vijf weken gisteren het indrukken van de $ 100 is het laagste niveau sinds medio -februari 2016. Deze situatie is des te verontrustender dat makelaars in waarde zijn gedaald.biotechbourse.fr/intercept-icpt-diffi...
GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC › Investigational New Drug (IND) application cleared by the FDA for the new indication of elafibranor in Primary Biliary Cholangitis (PBC), a rare disease with unmet need and only two orphan products approved to date Lille (France), Cambridge (Massachusetts, United States), November 4, 2016 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that the FDA has cleared the IND to proceed with the Phase II trial aimed at evaluating elafibranor in PBC. As previously announced, this trial is designed to be a multicenter, double-blind, randomized, placebo-controlled, Phase II study to evaluate the efficacy and safety of elafibranor after 12 weeks of treatment in patients with PBC and inadequate response to ursodeoxycholic acid. The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo. Secondary endpoints will include: ? ALP < 1.67 × upper limit of normal (ULN) and total bilirubin within normal limit and > 15% decrease in ALP ? Paris, Toronto, UK PBC scores ? Pruritus and QoL (Quality of Life) ? Safety of elafibranor in a PBC population PBC is a rare disease with unmet need. Current treatments only cure a fraction of the patient population, and/or generate important side effects such as pruritus, which is a major and wellknown symptom already affecting most PBC patients. Jean-François Mouney, CEO, Co-founder, and Chairman of the board of GENFIT commented: “We are satisfied with the progress made on the regulatory side in PBC. Our presence in this field is highly relevant given the profile of elafibranor, our proprietary molecule. We soon hope to be able to provide patients with a new, safe and well-tolerated therapeutic solution. Our involvement in PBC will continue to enrich our medical network thanks to our broad discussions and interactions we have with hepatologists. We value and cultivate a high level of collaboration with the medical community as it’s a way for us to ensure that the best decisions are made to address unmet medical needs in this field.”www.genfit.fr/wp-content/uploads/2016... Engels wat beter te lezen ;)
TraderRon schreef op 4 november 2016 09:37 :
Engels wat beter te lezen ;)
LIKE
A study on Elafibranor in PBC is planned to start H2 2016 Volgend deel van de puzzel is ingevuld, en mooi volgens planning! Vol vertrouwen de toekomst in!
JOVRO schreef op 2 november 2016 10:30 :
Phase 1 and preclinical
studies on on RoR Gamma T are planned H1 2017
Phase 2
A study on Elafibranor in PBC is planned to start H2 2016
A study on Elafibranor in Pediatric NASH is planned to start H2 2016
A study on Enafibranor in liver cirrhosis is planned H1 2017
einde fase 3 Elafibranor-Nash is in 2019 als ik me niet vergis
De fase 3 duurt nog ruim 2 jaar en het valt dan te hopen dat de uitkomst positief is en niet zoals fase 2 nogal mistig is anders krijg je weer een lange tijd van onzekerheid en misschien nog jarenlange vervolgonderzoeken Het grootste probleem bij NASH is dat het in een groot aantal gevallen een welvaartskwaal (verkeerde eetgewoontes en te weinig beweging) is en niet echt een ziekte Een middel die genfit aan het ontwikkelen is om deze ziekte (natuurlijke aanleg en erfelijkheid) in een vroegtijdig stadium te kunnen opsporen zie ik veel toekomst Men kan dan in een groot aantal gevallen volstaan met een aangepast dieet met als het nodig is een medicijn die oa leverfibrose voorkomt en op langere tijd bepaalde vormen van kanker ,het is wel de vraag hoe groot deze groep is Er zijn op dit moment veel bedrijven actief om een medicijn te ontwikkelen tegen NASH en ontstekingsziektes (fibrose) Gilead ,Galapagos Abbvie en nog vele anderen timmeren flink aan de weg We zullen moeten afwachten wie (kunnen er meer zijn)met de beste medicijn uit de bus zal komen
GENFIT : THIRD QUARTER 2016 FINANCIAL information (Unaudited financial information in accordance with IFRS) Cash and cash equivalents of €84.86 million as at September 30, 2016 Capital increases of a total gross amount of €78.5 million carried out successfully in October and November 2016 Revenues for first nine months of 2016 of €0.22 million Lille (France), Cambridge (Massachusetts, United States), November 8, 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced its cash and cash equivalents as at September 30, 2016 and its revenues for the first nine months of 2016. Cash position As at September 30, 2016, the Company's cash and cash equivalents ("Cash") amounted to €84.86 million compared with €64.32 million for the same period in 2015. Thereafter in early October 2016, GENFIT carried out a capital increase by way of a private placement, followed by, at the beginning of November 2016, a rights issue, which allowed the Company to raised a total gross amount of €78.5 million. The net proceeds of these two capital increases are thus added to the €84.86 in Cash as at September 30, 2016. Revenues Revenues for the first nine months of 2016 amount to €0.22 million compared to €0.45 million for the same period in 2015. Significant events of the third quarter 2016 Regarding elafibranor, the third quarter was marked by the filing of an IND (Investigational New Drug) for a Phase 2 trial in a new indication, Primary Biliary Cholangitis (PBC). The FDA has since approved this IND. In the framework of its program for the discovery and development of biomarkers in NASH, the Company also announced the launch of a large-scale qualification program of its proprietary non-invasive diagnostic based on miRNAs for the identification of NASH patients to be treated; the validation, with an independent cohort, of miRNAs discovered in the second half 2015; and the discovery of a new set of highly predictive miRNAs. Finally, in relation to the Company's TGFTX1 program, the Company identified several new RORgt inverse agonists as drug candidates for regulatory pre-IND studies. Upcoming event: AASLD Annual Meeting ("The Liver Meeting", Boston, November 11-15, 2016) The AASLD selected five GENFIT abstracts that will highlight post-hoc analyses of the GOLDEN-505 Phase 2 trial, the potential of non-invasive biomarkers identified by GENFIT to improve the identification of NASH patients to be treated, novel results of rodent NASH models compared with human NASH, and the importance of treating the histological parameters of NASH, and more precisely necro-inflammation, in the regression of fibrosis. On this occasion, GENFIT will host three events: An analyst and investor event, with the participation of four internationally-renowned experts, A scientific advisory board dedicated to biomarkers in NASH, and A scientific advisory board on fibrosis. About Elafibranor: Elafibranor is GENFIT's lead pipeline product. Elafibranor is an oral once-daily treatment, and a first-in-class drug acting via dual peroxisome proliferator-activated alpha/delta pathways developed to treat, in particular, nonalcoholic steatohepatitis (NASH). Elafibranor is believed to address multiple facets of NASH, including inflammation, insulin sensitivity, lipid/metabolic profile, and liver markers. About NASH: "NASH", or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with long term risk of progression to cirrhosis, a state where liver function is diminished, leading to liver insufficiency, and also progression to liver cancer. About PBC: "PBC" or Primary Biliary Cholangitis, is a chronic disease in which bile ducts in the liver are gradually destroyed. The damage to bile ducts can inhibit the liver's ability to rid the body of toxins, and can lead to scarring of liver tissue known as cirrhosis. About GENFIT: GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, Elafibranor, is currently in a Phase 3 study. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 110 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com www.holdthepresses.eu/2016/11/genfit-...
Beursblik: verkoopgolf zal van korte duur zijn Republikeinen zorgen waarschijnlijk voor nieuw groeiplan. (ABM FN) De markten zullen herstellen steunend op het vertrouwen in een nieuw groeiplan van de Republikeinen. Dit stelde martkstrateeg David Bianco van Deutsche Bank woensdag naar aanleiding van de overwinning van Donald Trump in een rapport gericht aan klanten. "We denken dat de boodschap van deze verkiezing de Amerikaanse eis naar een sterkere economische groei is. Een Republikeins Congres en president zullen waarschijnlijk de regelgeving verminderen en de vennootschapsbelasting genoeg verlagen om aan concurrentiekracht te winnen en geld uit het buitenland terug te brengen", stelde Bianco. Volgens de analist is deze ommezwaai naar Republikeins terrein goed voor de markten. Een verkoopgolf zal volgens hem dan ook van korte duur zijn en vooral farmabedrijven zullen het goed doen. Door: ABM Financial News.pers@abmfn.be Redactie: +32(0)78 486 481 Copyright ABM Financial News. All rights reserved (END) Dow Jones Newswires November 09, 2016 09:51 ET (14:51 GMT)
seekingalpha.com/author/logribel-bios... Interessant inzake genfits NASH potentieel
NASH is a promising market, since the disease already affects 6 to 15 million people in the U.S. and unfortunately, the number is estimated to grow over time because of the trend in obesity and bad eating habits. To make a comparison, the number of people living with HCV in 2009 (before Gilead's blockbuster drugs) was estimated to be around 3.2 million. In financial terms, Deutsche Bank estimated that the market will be worth between $35 and $40 Billion by 2025 . While there are no treatments for NASH at the moment, many companies can see the market potential. Genfit (OTCPK:GNFTF), Galmed (NASDAQ:GLMD), Intercept (NASDAQ:ICPT) and Novo Nordisk (NYSE:NVO) are trying to develop treatments and even the giant of dermatology Allergan (NYSE:AGN) has recently entered the market through the acquisition of Tobira Therapeutics (NASDAQ:TBRA) and Akarna.
Brouya schreef op 2 december 2016 10:02 :
NASH is a promising market, since the disease already affects 6 to 15 million people in the U.S. and unfortunately, the number is estimated to grow over time because of the trend in obesity and bad eating habits. To make a comparison, the number of people living with HCV in 2009 (before Gilead's blockbuster drugs) was estimated to be around 3.2 million. In financial terms,
Deutsche Bank estimated that the market will be worth between $35 and $40 Billion by 2025 . While there are no treatments for NASH at the moment,
many companies can see the market potential. Genfit (OTCPK:GNFTF), Galmed (NASDAQ:GLMD), Intercept (NASDAQ:ICPT) and Novo Nordisk (NYSE:NVO) are trying to develop treatments and even the giant of dermatology Allergan (NYSE:AGN) has recently entered the market through the acquisition of Tobira Therapeutics (NASDAQ:TBRA) and Akarna.
Dit is ook nog een artikel..met ongeveer zelfde strekking:decisionresourcesgroup.com/drg-blog/n...
Dank speurneus voor de link. ik kende het artikel niet. positief nieuws is altijd welkom.
Dit kan nog leuk worden!!!!French Drugmaker Genfit Said to Explore Options Including Sale by Manuel Baigorri and Dinesh Nair December 5, 2016 — 1:56 PM EST December 5, 2016 — 1:56 PM EST Genfit said to work with advisers, also consider partnerships NASH treatment maker said in talks with other drug companies French drugmaker Genfit is working with advisers to explore options, including a sale of the business, as its treatment for a type of liver disease linked to obesity attracts interest from other pharmaceutical companies, according to people familiar with the matter. The company, which is developing a drug for nonalcoholic steatohepatitis or NASH, is also weighing licensing agreements, partnerships or joint ventures, one of the people said, asking not to be identified as the considerations are private. The company is in early discussions with other drugmakers, though the talks may not lead to a deal, the person said. Genfit shares have declined 38 percent this year, giving it a market value of about $654 million. A spokesman for Genfit declined to comment. Pharmaceutical companies including Sanofi, Novartis AG and Shire Plc may be interested in Genfit, people familiar with the matter said last year. Genfit is developing a drug called elafibranor, and in October raised about 78.5 million euros ($84.6 million) to continue to fund the product. So far, no treatments have been approved to treat NASH, which is a slow developing disease that occurs when fat accumulates in the liver, causing inflammation and damage. The condition may ultimately lead to cirrhosis. It will be the leading cause of liver transplants by 2020, according to Allergan Plc, which has been acquiring companies developing treatments this year. More than 12 percent of adults in the U.S. may have the condition, according to Genfit. A number of other companies are also racing to develop treatments for the disease, including Intercept Pharmaceuticals Inc. and Gilead Sciences Inc.www.bloomberg.com/news/articles/2016-...
Als dit klopt, dan zien ze heil meer in hun NASH-middel. Het zou een overname uit armoe zijn.
DeZwarteRidder schreef op 6 december 2016 08:51 :
Als dit klopt, dan zien ze heil meer in hun NASH-middel.
Het zou een overname uit armoe zijn.
je bedoelt geen heil meer....
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee